Can a shot of your own blood platelets help a repaired meniscus heal?
NCT ID NCT07815743
First seen Sep 11, 2026 · Last updated Sep 11, 2026
Summary
Researchers are testing whether adding leukocyte-poor platelet-rich plasma during meniscus repair surgery improves knee function and reduces pain compared with standard repair alone. The study enrolls 62 adults aged 18 to 40 with repairable meniscal tears. Participants receive either the plasma injection between the sutured edges or conventional repair, and researchers track knee function, pain, return to usual activities, and complications over six months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- leukocyte-poor platelet-rich plasma, a concentrate of the patient's own blood platelets
- What this could lead to
- If it works, surgeons could add a patient's own blood platelets during meniscus repair to improve knee function and speed the return to normal activity.
- What could go wrong
- This is a small, single-center study with only six months of follow-up, so any benefit may be modest or fade. Platelet-rich plasma has shown mixed results in other joint treatments, and the injection adds cost and a small risk of infection or knee irritation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 62 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 40 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age 18 to 40 years, with confirmed skeletal maturity. 2. Indication for primary meniscal repair, with no previous interventions in the same knee joint. 3. Repairable meniscal lesions, including horizontal, vertical longitudinal, radial, oblique, or complex tear patterns, provided that biomechanical stability criteria are met after suturing. 4. Lesions located in anatomical zones with healing potential (red-red or red-white zones), or lesions in the white-white zone considered repairable by the treating surgeon. 5. Ability to provide informed consent and comply with the 6-month clinical follow-up schedule. Exclusion Criteria: 1. Metabolic or systemic diseases that may impair healing (e.g., uncontrolled diabetes). 2. Active rheumatic or inflammatory diseases, such as rheumatoid arthritis. 3. Previous surgery in the same knee joint. 4. Recent use of nonsteroidal anti-inflammatory drugs (NSAIDs) that may interfere with the effects of PRP. 5. Advanced chondral damage, defined as Outerbridge grade III or IV, or significant osteoarthritis. 6. Irreparable meniscal lesions or cases not considered candidates for meniscal repair. 7. Known allergy or hypersensitivity to PRP or components used in its preparation. 8. Inability to complete the required 6-month clinical follow-up.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Meniscal tears are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hospital Universitario "Dr. José Eleuterio González"
Monterrey, Nuevo León, 64460, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.